Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 2
1967 1
1968 1
1969 1
1970 1
1996 1
2003 3
2007 1
2008 2
2009 4
2010 2
2011 2
2012 1
2013 4
2014 5
2015 3
2016 8
2017 3
2018 6
2019 12
2020 5
2021 8
2022 10
2023 8
2024 10
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Results by year

Filters applied: . Clear all
Page 1
Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease.
Younossi ZM, Alqahtani SA, Alswat K, Yilmaz Y, Keklikkiran C, Funuyet-Salas J, Romero-Gómez M, Fan JG, Zheng MH, El-Kassas M, Castera L, Liu CJ, Wai-Sun Wong V, Zelber-Sagi S, Allen AM, Lam B, Treeprasertsuk S, Hameed S, Takahashi H, Kawaguchi T, Schattenberg JM, Duseja A, Newsome PN, Francque S, Spearman CW, Castellanos Fernández MI, Burra P, Roberts SK, Chan WK, Arrese M, Silva M, Rinella M, Singal AK, Gordon S, Fuchs M, Alkhouri N, Cusi K, Loomba R, Ranagan J, Eskridge W, Kautz A, Ong JP, Kugelmas M, Eguchi Y, Diago M, Yu ML, Gerber L, Fornaresio L, Nader F, Henry L, Racila A, Golabi P, Stepanova M, Carrieri P, Lazarus JV; Global NASH Council. Younossi ZM, et al. Among authors: nader f. J Hepatol. 2024 Mar;80(3):419-430. doi: 10.1016/j.jhep.2023.11.004. Epub 2023 Nov 18. J Hepatol. 2024. PMID: 37984709
Brazilian cave heritage under siege.
Ferreira RL, Bernard E, da Cruz Júnior FW, Piló LB, Calux A, Souza-Silva M, Barlow J, Pompeu PS, Cardoso P, Mammola S, García AM, Jeffery WR, Shear W, Medellín RA, Wynne JJ, Borges PAV, Kamimura Y, Pipan T, Hajna NZ, Sendra A, Peck S, Onac BP, Culver DC, Hoch H, Flot JF, Stoch F, Pavlek M, Niemiller ML, Manchi S, Deharveng L, Fenolio D, Calaforra JM, Yager J, Griebler C, Nader FH, Humphreys WF, Hughes AC, Fenton B, Forti P, Sauro F, Veni G, Frumkin A, Gavish-Regev E, Fišer C, Trontelj P, Zagmajster M, Delic T, Galassi DMP, Vaccarelli I, Komnenov M, Gainett G, da Cunha Tavares V, Kováč Ľ, Miller AZ, Yoshizawa K, Di Lorenzo T, Moldovan OT, Sánchez-Fernández D, Moutaouakil S, Howarth F, Bilandžija H, Dražina T, Kuharić N, Butorac V, Lienhard C, Cooper SJB, Eme D, Strauss AM, Saccò M, Zhao Y, Williams P, Tian M, Tanalgo K, Woo KS, Barjakovic M, McCracken GF, Simmons NB, Racey PA, Ford D, Labegalini JA, Colzato N, Ramos Pereira MJ, Aguiar LMS, Moratelli R, Du Preez G, Pérez-González A, Reboleira ASPS, Gunn J, Mc Cartney A, Bobrowiec PED, Milko D, Kinuthia W, Fischer E, Meierhofer MB, Frick WF. Ferreira RL, et al. Among authors: nader fh. Science. 2022 Mar 18;375(6586):1238-1239. doi: 10.1126/science.abo1973. Epub 2022 Mar 17. Science. 2022. PMID: 35298256 No abstract available.
The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease.
Younossi ZM, AlQahtani SA, Funuyet-Salas J, Romero-Gómez M, Yilmaz Y, Keklikkiran C, Alswat K, Yu ML, Liu CJ, Fan JG, Zheng MH, Burra P, Francque SM, Castera L, Schattenberg JM, Newsome PN, Allen AM, El-Kassas M, Treeprasertsuk S, Hameed S, Wai-Sun Wong V, Zelber-Sagi S, Takahashi H, Kawaguchi T, Castellanos Fernández MI, Duseja A, Arrese M, Rinella M, Singal AK, Gordon SC, Fuchs M, Eskridge W, Alkhouri N, Cusi K, Loomba R, Ranagan J, Kautz A, Ong JP, Kugelmas M, Eguchi Y, Diago M, Gerber L, Lam B, Fornaresio L, Nader F, Spearman CW, Roberts SK, Chan WK, Silva M, Racila A, Golabi P, Ananchuensook P, Henry L, Stepanova M, Carrieri P, Lazarus JV; Global NASH Council. Younossi ZM, et al. Among authors: nader f. JHEP Rep. 2024 Mar 12;6(7):101066. doi: 10.1016/j.jhepr.2024.101066. eCollection 2024 Jul. JHEP Rep. 2024. PMID: 39022387 Free PMC article.
Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis.
Younossi ZM, Stepanova M, Racila A, Henry L, Labriola D, Taub R, Nader F. Younossi ZM, et al. Among authors: nader f. Hepatology. 2024 Sep 6. doi: 10.1097/HEP.0000000000001084. Online ahead of print. Hepatology. 2024. PMID: 39250515
Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis.
Younossi ZM, Stepanova M, Nader F, Loomba R, Anstee QM, Ratziu V, Harrison S, Sanyal AJ, Schattenberg JM, Barritt AS, Noureddin M, Bonacci M, Cawkwell G, Wong B, Rinella M; RandomizEd Global Phase 3 Study to Evaluate the Impact on NASH with FibRosis of Obeticholic Acid TreatmEnt (REGENERATE) Study Investigators. Younossi ZM, et al. Among authors: nader f. Clin Gastroenterol Hepatol. 2022 Sep;20(9):2050-2058.e12. doi: 10.1016/j.cgh.2021.07.020. Epub 2021 Jul 15. Clin Gastroenterol Hepatol. 2022. PMID: 34274514 Free article. Clinical Trial.
89 results